. Author manuscript; available in PMC: 2020 Feb 10.

Published in final edited form as: Ann N Y Acad Sci. 2015 Mar;1338:1–15. doi: 10.1111/nyas.12723

Table 6.

Summary of the meta-analyses and trials on treatment of hypertension and stroke outcome

Author	Study type	N	Primary versus secondary stroke prevention	Treatment group; blood pressure target	Comparison group	Stroke outcome
Sipahi et al³⁷	Meta-analysis	70,664	Primary	<140/90	Placebo	RR 0.78 (95% CI 0.71–0.86)
Lee et al.³⁸	Meta-analysis	42,572	Primary	SBP < 130 mmHg compared to 130–139 mmHg	Placebo	RR 0.80 (0.70–0.92)
Cushman et al³⁹ (ACCORD trial)	RCT	4733	Primary	Diabetic patients, SBP < 120 mmHg	SBP target < 140 mmHg	HR 0.59, 95% CI 0.39–0.89
Okin et al.⁴⁰ (LIFE trial)	RCT	9193	Primary	SBP target < 130 mmHg and SBP target 131–141 mmHg	SBP target ≥ 142 mmHg	SBP < 130 mgHg: OR 1.08, 95% CI 0.79–1.47 SBP 131–141 mmHg: OR 1.06, 95% CI 0.47–0.79
McAllister et al.⁴¹	Meta-analysis	80,594	Primary	Patients with CVD, no HTN	Placebo	OR 0.91, 95% CI 0.86–0.97
Thompson et al.⁴²	Meta-analysis	21,872	Primary	Patients with CVD, no HTN	Placebo	0.77, 95% CI 0.61–0.98
Benavente et al⁴⁹ (SPS3 trial)	RCT	3020	Secondary	SBP target <130 mmHg 2 weeks after lacunar stroke	SBP 130–149 mmHg	HR0.81,95%CI 0.6–1.03

RCT, randomized clinical trial; SBP, systolic blood pressure; RR, relative risk; HR, hazard ratio; OR, odds ration; CVD, cardiovascular disease; HTN, hypertension; ACCORD, Action to Control Cardiovascular Risk in Diabetes; LIFE, Losartan Intervention For Endpoint reduction in hypertension; SPS3 trial, Secondary Prevention of Small Subcortical Strokes trial.